Compositions, methods and kits for identying protein-protein interaction disrupting agents

• US 20040067483A1
• Filed: 11/17/2003
• Published: 04/08/2004
• Est. Priority Date: 12/18/2000
• Status: Abandoned Application

• Current Assignee: National Research Council Canada
• Original Assignee: National Research Council Canada
• Inventors: Zhao, Hui-Fen, Shen, Shi-Hsiang
• Application Number:
  US10/450,777
• Publication Number:
  US 20040067483A1
• Time in Patent Office: Days
• US Class Current: 435/4
• CPC Class Codes: C12N 15/1055 Protein x Protein interaction, e.g. two hybrid selection
• CPC Class Codes: C12N 15/635 Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline

Abstract

The present invention provides compositions, methods, and kits for identifying agents that are capable of disrupting protein-protein interaction in a mammalian reverse two-hybrid system. A tetracycline repressor protein was fused with the inhibitory KRAB domain as a suppressor to tightly regulate the reverse two-hybrid system for mammalian cells. Binding of the chimeric protein to the tetracycline operator sequence provided within a promoter entirely suppressed the expression of two interactive proteins. When both an inducer and a candidate protein-protein interaction disrupting agent such as a drug were added in the cell culture together, the reporter gene was either activated by the interaction of protein-pair if the drug was ineffective or remained silent due to the disruption of the protein-protein interaction by the effective drug. The plasmids for the suppressor and the reporter were integrated into chromosomes. Constructs for the expression of interactive proteins were either stably or transiently transfected into the cells. The utility of this system for screening drugs, particularly for enzyme inhibitor drugs, was demonstrated by using two well characterized interactions of the type I receptor for TGFβ with FKPB12 and the EGF receptor with p85. The interaction between TGFβBI and FKPB12 or between EGF receptor and p85 were disrupted by FK506 and kinase inhibitor AG1478, respectively. The mammalian reverse two-hybrid system of the present invention can also be used for high throughput screening of compounds that disrupt protein-protein interactions.

Claims

1. A mammalian reverse two-hybrid system for identifying a change in protein-protein interaction comprising:

a suppressor construct comprising a constitutive promoter operably linked to a repressor protein coding sequence;

an interactive fusion protein coding construct comprising a promoter operably linked to a repressible operator repressible by a repressor protein coded by said repressor protein coding sequence, a first interactive protein coding sequence fused in frame with a transcriptional activation domain protein coding sequence and a second interactive protein coding sequence fused in frame with a DNA binding domain protein coding sequence; and

,

a reporter construct comprising a DNA binding element bindable to said DNA binding domain protein operably linked to a minimal promoter and a reporter coding sequence.

2. The mammalian reverse two-hybrid system according to claim 1 wherein said interactive fusion protein coding construct comprises:

a first interactive protein-transcriptional activation domain fusion protein coding construct comprising a promoter operably linked to a repressible operator repressible by a repressor protein coded by said repressor protein coding sequence and a first interactive protein coding sequence fused in frame with a transcriptional activation domain protein coding sequence; and

,

a second interactive protein-DNA binding domain fusion protein gene construct comprising a promoter operably linked to a repressible operator repressible by a repressor protein coded by said repressor protein coding sequence, a second interactive protein coding sequence fused in frame with a DNA binding domain protein coding sequence.

3. The mammalian reverse two-hybrid system according to claim 1 additionally comprising at least one internal ribosome entry site (IRES) sequence.

4. The mammalian reverse two-hybrid system according to claim 1, wherein said first interactive protein coding sequence fused in frame with a transcriptional activation domain protein coding sequence is operably linked to said second interactive protein coding sequence fused in frame with a DNA binding domain protein coding sequence through an internal ribosome entry site (IRES) sequence.

5. The mammalian reverse two-hybrid system according to claim 1, wherein said reporter construct additionally comprises a second reporter coding sequence operably linked to a said reporter coding sequence.

6. The mammalian reverse two-hybrid system according to claim 5, wherein said first reporter coding sequence is operably linked to said second reporter coding sequence through an internal ribosome entry site (IRES) sequence.

7. The mammalian reverse two-hybrid system according to claim 1 wherein in said suppressor construct said constitutive promoter is selected from the group consisting of promoters from human cytomegalovirus (CMV), SV40, respiratory syncytial virus (RSV), EF1, and thymine kinase (TK) genes.

8. The mammalian reverse two-hybrid system according to claim 1 wherein in said suppressor construct said repressor protein coding sequence codes for a protein selected from the group consisting of Lac repressor, λ

repressor, Tet repressor, and hybrid-Tet repressor (TetR).

9. The mammalian reverse two-hybrid system according to claim 8, wherein said hybrid-TetR has the TetR protein linked with the KRAB domain of the human transcription suppressor Koxl by a nuclear localization sequence (NLS).

10. The mammalian reverse two-hybrid system according to claim 1 wherein said suppressor construct additionally comprises a drug selective marker which provides resistance to a drug.

11. The mammalian reverse two-hybrid system according to claim 1 wherein in said interactive fusion protein coding construct said promoter and repressible operator are selected from the group consisting of a core human cytomegalovirus (CMV), SV40, respiratory syncytial virus (RSV), EF1 and thymine kinase (TK) promoter linked with tetracycline operator.

12. The mammalian reverse two-hybrid system according to claim 1 wherein said interactive fusion protein coding construct codes for a protein selected from the group consisting of receptors, adapters, affectors and enzymes.

13. The mammalian reverse two-hybrid system according to claim 12, wherein said first interactive protein coding sequence codes for a disease-related signalling molecule.

14. The mammalian reverse two-hybrid system according to claim 1 wherein said transcriptional activation domain coding sequence is selected from the group consisting of GAL4, B42, VP16 and NF-kB p65 coding sequences.

15. The mammalian reverse two-hybrid system according to claim 1 wherein said second interactive protein coding sequence codes for a protein selected from the group consisting of a protease, a phosphatase, a kinase, a receptor and an enzyme.

16. The mammalian reverse two-hybrid system according to claim 15, wherein said kinase is a disease-related kinase.

17. The mammalian reverse two-hybrid system according to claim 16, wherein said disease-related kinase is selected from the group consisting of EGFR, PDGFR, Her2, VEGFR, Met, FGFR, IGFR, insulin receptor, JAKs, PKA, PKC, MAP kinase, ZAP70, v-Ab1, and Lck, Lyn, or other Src-like kinase.

18. The mammalian reverse two-hybrid system according to claim 1 wherein the DNA binding domain coding sequence is selected from the group consisting of Gal4 DNA binding domain, Lac repressor, Tet repressor, lambda repressor, Lax A DNA binding sequence, NF-kB p65 and p53.

19. The mammalian reverse two-hybrid system according to claim 3 or 5, wherein in said internal ribosome entry site (IRES) sequence is selected from the group consisting of a synthetic IRES sequence and an encephalomyocarditis virus (EMCV) IRES.

20. The mammalian reverse two-hybrid system according to claim 1 wherein in said reporter construct said DNA binding element is selected from the group consisting of Gal4 binding element, Lac operator, Tet operator, lambda operator, Lax A binding element and p53 binding sites.

21. The mammalian reverse two-hybrid system according to any one of claims 1, 4, and 5, wherein in said reporter construct said promoter is selected from the group consisting of a minimal promoter from human cytomegalovirus (CMV) promoter, SV40 early promoter, adenovirus E1b promoter, respiratory syncytial virus (RSV) promoter, EF1 promoter and thymine kinase (TK) promoter.

22. The mammalian reverse two-hybrid system according to any one of claims 1, 4, and 5, wherein said reporter coding sequence codes for a protein selected from the group consisting of a green fluorescent protein (GFP) or GFP-active derivative, a luciferase, a β

-lactamase, a β

-galactosidase, an alkaline phosphatase and chloramphenicol acetyl transferase.

23. A plasmid comprising the mammalian reverse two-hybrid system according to claim 1.

24. A two-plasmid set comprising the mammalian reverse two-hybrid system according to claim 1, wherein said suppressor construct and said reporter construct are provided on a first plasmid and said first interactive protein-transcriptional activation domain fusion protein coding construct and said second interactive protein-DNA binding domain fusion protein coding construct together are provided on a second plasmid.

25. A mammalian cell comprising a mammalian reverse two-hybrid system according to claim 1.

26. A mammalian cell according to claim 25 wherein said mammalian reverse two-hybrid system is integrated into a chromosome in said cell.

27. A method for identifying a change in protein-protein interaction comprising:

subjecting a mammalian reverse two-hybrid system according to any one of claims 1 to 22 in a cell to an inducer and a test protein-protein interaction disrupting agent;

and assaying said cell for expression or non-expression of said reporter coding sequence, non-expression of said reporter coding sequence being indicative of disrupting ability of said test protein-protein interaction disrupting agent.

28. The method of claim 27 wherein said disrupting agent is an indirect disrupting agent being tested for an ability to inhibit activity of a disease-related enzyme.

30. The method of identifying a change in protein-protein interaction according to claim 28 wherein said cell is a mammalian cell.

29. A method for identifying a change in protein-protein interaction comprising:

(a) stably introducing a suppressor construct and a reporter construct in a cell;

(b)(i) stably introducing a first interactive protein-transcriptional activation domain fusion protein coding construct and a second interactive protein-DNA binding domain fusion protein coding construct into said cell;

or

(b)(ii) transiently introducing a first interactive protein-transcriptional activation domain fusion protein coding construct and a second interactive protein-DNA binding domain fusion protein coding construct into said cell;

(c) subjecting a cell resulting from step (b)(i) or (b)(ii) to an inducer and a test protein-protein interaction disrupting agent;

(d) assaying said subjected cell for the non-expression and expression of said reporter coding sequence; and

,

(e) identifying said protein-protein interaction disrupting agent based on non-expression of said reporter coding sequence.

31. A kit for identifying a change in protein-protein interaction comprising:

one or more aliquots of a suppressor construct, a first interactive protein-transcriptional activation domain fusion protein coding construct, a second interactive protein-DNA binding domain fusion protein coding construct, and a reporter construct on one or more plasmids; and

,

one or more aliquots of a reagent, cell, and apparatus needed for conducting a method for identifying a change in protein-protein interaction.

32. A kit for identifying a change in protein-protein interaction comprising:

one or more aliquots of one or more constructs on one or more plasmids as defined in claim 31;

one or more aliquots of a cell containing one or more constructs as defined in claim 31;

and,

one or more aliquots of a reagent and apparatus needed for conducting a method for identifying a change in protein-protein interaction.